The National Institute for Health and Care Excellence (NICE) has provisionally recommended against the use of lenalidomide, marketed as Revlimid, for treating myelofibrosis in England. This rare blood cancer affects the bone marrow, leading to abnormal blood cell production and often severe anaemia.
The draft guidance specifically concerns patients with anaemia who also carry a specific genetic mutation known as SF3B1. Revlimid, developed by Bristol Myers Squibb, was being considered as a potential treatment option for this subgroup of patients, aiming to alleviate the anaemia and reduce the need for blood transfusions.
NICE's decision stems primarily from concerns over the drug's cost-effectiveness. While acknowledging Revlimid's potential benefits for certain patients, the independent appraisal committee concluded that the evidence presented did not sufficiently demonstrate that the drug offered enough value for money to justify its routine funding by the NHS at its current price. Myelofibrosis is a chronic and progressive condition, and effective treatments are crucial for improving patients' quality of life and managing symptoms.
Myelofibrosis is a relatively uncommon condition, affecting approximately one in 100,000 people in the UK. Symptoms can include fatigue, shortness of breath due to anaemia, an enlarged spleen, and bone pain. Current treatments often focus on managing symptoms and improving blood counts, which can include blood transfusions, erythropoiesis-stimulating agents, and other targeted therapies.
This provisional recommendation opens a consultation period, allowing stakeholders, including patient groups, healthcare professionals, and the drug manufacturer, to submit further evidence and comments. NICE will review all submitted feedback before issuing its final guidance. A rejection at this stage can be a significant setback for patients hoping for new treatment options, highlighting the ongoing tension between drug innovation, patient needs, and healthcare budget constraints.
The implications of a final negative recommendation would mean that Revlimid would not be routinely commissioned by the NHS for myelofibrosis patients in England, potentially limiting access for those who might benefit from it. Patients currently receiving the drug through other means, such as clinical trials or compassionate use programmes, may not be directly affected in the short term, but future access for new patients would be restricted.